NUTRA PHARMA CORP vs. NVIDIA Corporation
NUTRA PHARMA CORP and NVIDIA Corporation are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| NPHC | NVDA | |
|---|---|---|
| Market Cap | — | $5.33 trillion |
| Revenue (TTM) | — | $302.97 billion |
| Net Income (TTM) | — | $192.88 billion |
NPHC and NVDA split the size & scale factors evenly.
Valuation
| NPHC | NVDA | |
|---|---|---|
| P/E Ratio | — | 27.49 |
| Price / Book | — | 23.28 |
| Price / Sales | — | 17.60 |
NPHC and NVDA split the valuation factors evenly.
Profitability
| NPHC | NVDA | |
|---|---|---|
| Net Margin | — | 63.66% |
| Return on Equity | — | 84.23% |
NPHC and NVDA split the profitability factors evenly.
Dividend
| NPHC | NVDA | |
|---|---|---|
| Dividend Yield | — | 0.46% |
| Payout Ratio | — | 12.64 |
NPHC and NVDA split the dividend factors evenly.
Risk & Sentiment
| NPHC | NVDA | |
|---|---|---|
| Short Interest | — | 0.07% |
NPHC and NVDA split the risk & sentiment factors evenly.
Dig deeper: NPHC overview, NPHC financials, NVDA overview, NVDA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.